The NIMH Chemical Synthesis Program was established by NIMH in 1959 and has been maintained since 1991 by the Psychotherapeutic Drug Discovery and Development program in the Division of Neuroscience and Behavioral Science at NIMH. Together with other initiatives such as the NovaScreen and Natural Products Screening Projects, the Chemical Synthesis program is an important component of NIMH's efforts to promote progress in basic and applied neuroscience. The Program is similar to others supported by NCI (antitumor compounds), NICHD (contraceptives) and NIDA (drugs of abuse). The fundamental purpose of the Chemical Synthesis Program is to identify, synthesize and distribute novel, or known but unavailable, chemical compounds of interest to the research community for use in studies related to the area of mental health. Generally, compounds that are commercially available or are provided gratis by a pharmaceutical firm are excluded from this program. Occasionally, the Program will purchase a compound for one or more investigators when the quantity required would be prohibitively expensive for an individual grant budget. Such purchases are frequently requested by researchers in third-world countries, and are decided on a case-by-case basis. The Program is available to all qualified scientists involved in research related to the field of mental health, and is not restricted to NIMH grantees. The compounds provided by the Chemical Synthesis Program have a variety of uses: as pharmacological tools, as reference standards, as biochemical or neuroanatomical markers, as biological precursors for metabolic studies, for use in elucidating structure-activity relationships, for enzyme studies, as radiolabeling precursors, and for a variety of other purposes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research and Development Contracts (N01)
Project #
N01MH030003-007
Application #
2450987
Study Section
Project Start
1993-09-30
Project End
1997-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Sigma-Aldrich Research Biochemical
Department
Type
DUNS #
City
Natick
State
MA
Country
United States
Zip Code
01760
Tomiyama, Katsunori; McNamara, Fergal N; Clifford, Jeremiah J et al. (2004) Comparative phenotypic resolution of spontaneous, D2-like and D1-like agonist-induced orofacial movement topographies in congenic mutants with dopamine D2 vs. D3 receptor ""knockout"". Synapse 51:71-81
Adachi, Kazunori; Hasegawa, Megumi; Fujita, Satoshi et al. (2003) Prefrontal, accumbal [shell] and ventral striatal mechanisms in jaw movements and non-cyclase-coupled dopamine D1-like receptors. Eur J Pharmacol 473:47-54
Ortego, Javier; Wollmann, Guido; Coca-Prados, Miguel (2002) Differential regulation of gene expression of neurotensin and prohormone convertases PC1 and PC2 in the bovine ocular ciliary epithelium: possible implications on neurotensin processing. Neurosci Lett 333:49-53
Tomiyama, K; McNamara, F N; Clifford, J J et al. (2002) Phenotypic resolution of spontaneous and D1-like agonist-induced orofacial movement topographies in congenic dopamine D1A receptor 'knockout' mice. Neuropharmacology 42:644-52
Louis, Simon N; Rezmann-Vitti, Linda A; Nero, Tracy L et al. (2002) CoMFA analysis of the human beta(1)-adrenoceptor binding affinity of a series of phenoxypropanolamines. Eur J Med Chem 37:111-25
Hasegawa, M; Adachi, K; Nakamura, S et al. (2001) Ventral striatal vs. accumbal (shell) mechanisms and non-cyclase-coupled dopamine D(1)-like receptors in jaw movements. Eur J Pharmacol 423:171-8
Patni, A K; Gupta, S; Sharma, A et al. (2001) Role of intracellular calcium in the spermicidal action of 2',4'-dichlorobenzamil, a novel contact spermicide. J Pharm Pharmacol 53:1387-92
Harris, J; Drew, L J; Chapman, V (2000) Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport 11:2817-9
Winsauer, P J; Rodriguez, F H; Cha, A E et al. (1999) Full and partial 5-HT1A receptor agonists disrupt learning and performance in rats. J Pharmacol Exp Ther 288:335-47
Yousif, M H; Oriowo, M A (1999) Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments. Pharmacol Res 40:415-21

Showing the most recent 10 out of 17 publications